Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

NEW YORK--()--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

  • 9th Annual SVB Leerink Global Healthcare Conference, New York, N.Y.
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, February 25, 2020, at 10:30 a.m. Eastern Time.
  • Cowen’s 40th Annual Health Care Conference, Boston, M.A.
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
  • Annual Barclays Global Healthcare Conference, Miami, F.L.
    • Tuesday, March 10, 2020
  • Oppenheimer’s 30th Annual Healthcare Conference, New York, N.Y.
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, March 18, 2020, at 11:30 a.m. Eastern Time

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket’s pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.

Contacts

Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
investors@rocketpharma.com

Contacts

Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
investors@rocketpharma.com